Company: CGC
Filing Date: 2025-05-29
Form Type: POSASR
Source: 0001104659-25-054285
Chunk: 53

Company: Canopy Growth Corp
Filing Date: 2025-05-29
Form: POSASR
Chunk 53
---
 consumer demand for cannabis and hemp products; the implementation and effectiveness of key personnel changes; risks related to stock exchange restrictions; risks related to the protection and enforcement of our intellectual property rights; the risks related to the Exchangeable Shares having different rights from Common Shares and there may never be a trading market for the Exchangeable Shares; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; and the factors discussed under the heading “Risk Factors” in this prospectus supplement and in the documents incorporated by reference herein, including in the Annual Report and any subsequently filed Quarterly Reports on Form 10-Q.

You should read carefully the risk factors described herein and in the documents incorporated by reference in this prospectus supplement for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking statements.**

<div align='center'>S-11</div>

TABLE OF CONTENTS

### USE OF PROCEEDS
We are offering up to $172,069,635 of Common Shares in this offering, together with sales pursuant to the Concurrent Canadian Offering after the date hereof. The net proceeds from this offering and the Concurrent Canadian Offering, if any, are not determinable in light of the nature of such offerings. The net proceeds of any given sale of Common Shares through the Agents in an “at-the-market” offering will represent the gross proceeds after deducting the Commission, the expenses of the distribution and any transaction or filing fees imposed by any governmental, regulatory or self-regulatory organization in connection with the sales. The proceeds we receive from sales in this offering and the Concurrent Canadian Offering will depend on the number of Common Shares actually sold in this offering and the Concurrent Canadian Offering and the offering price of such Common Shares. See “Plan of Distribution”.

We currently intend to use the net proceeds from the sale of our Common Shares offered by this prospectus supplement, together with the net proceeds of the Concurrent Canadian Offering, for investments in businesses and/or to fund any potential future acquisitions and for working capital and general corporate purposes, which may include the repayment of indebtedness, including a portion of the amounts outstanding under our secured $750 million first lien senior term loan facility, which currently has an aggregate principal amount outstanding of $150.6 million (the “Credit Facility”) pursuant to a term loan credit agreement entered into by us on March 18, 2021, as amended.

The Credit Facility matures on September 18, 2027, and interest on amounts outstanding under the Credit Facility is calculated at